Clinical Trials Logo

Relapse Multiple Myeloma clinical trials

View clinical trials related to Relapse Multiple Myeloma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06171685 Not yet recruiting - Clinical trials for Refractory Multiple Myeloma

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Start date: July 31, 2024
Phase: Phase 2
Study type: Interventional

This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.

NCT ID: NCT04670055 Not yet recruiting - Clinical trials for Refractory Multiple Myeloma

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

NCT ID: NCT04541368 Not yet recruiting - Clinical trials for Relapse Multiple Myeloma

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Start date: December 31, 2020
Phase: Early Phase 1
Study type: Interventional

Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy